Zobrazeno 1 - 10
of 269
pro vyhledávání: '"C Sillaber"'
Autor:
B. Jilma, J. C. Gilbert, M. Fillitz, T. Schenk, Georg Gelbenegger, R. Cartwright, S. D'Sa, U. Jaeger, C. Sillaber, C. Schoergenhofer
Publikováno v:
HemaSphere. 3:408-409
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39b9d5d0b3373a4766773b547263ab10
https://doi.org/10.1097/01.hs9.0000561900.82596.8f
https://doi.org/10.1097/01.hs9.0000561900.82596.8f
Autor:
Jutta Ackermann, C Sillaber, M. Kees, G. Dimou, Heinz Gisslinger, Johannes Drach, Klaus Lechner
Publikováno v:
Leukemia & Lymphoma. 44:1943-1946
Remarkable results of the treatment of refractory multiple myeloma with thalidomide have been reported. In most preceding studies, the given thalidomide dose was escalated to a maximum tolerated dose of up to 800 mg/d. The frequency of adverse effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88868c25b3d40fd990303ce2c733b8e3
https://doi.org/10.1080/1042819031000123492
https://doi.org/10.1080/1042819031000123492
Autor:
Bernd R. Binder, Klaus Lechner, Peter Valent, Mehrdad Baghestanian, Hans Bankl, W. R. Sperr, C Sillaber, Johann Wojta
Publikováno v:
Thrombosis and Haemostasis. 87:786-790
SummaryVenous thromboembolism represents a significant cause of morbidity worldwide. The factors that underly thrombophilia are manifold. The concept of Virchow defines the well known triad of stasis, humoral factors, and pathologies of the vascular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c547c4f623c207422e3cfe427f71f2ad
https://doi.org/10.1055/s-0037-1613084
https://doi.org/10.1055/s-0037-1613084
Autor:
A. Gaiger, Sabine Walchshofer, Peter Valent, Ingrid Simonitsch, Isabella Mosberger, C Sillaber, Andreas Chott, Klaus Lechner
Publikováno v:
Tissue Antigens. 53:559-568
In order to determine the relationship between bone marrow (bm) endosteal cells (EDC) and hemopoietic progenitors, we have analyzed the immunophenotype of EDC using various antibodies (Ab) against mesenchymal antigens. The Ab were applied on paraffin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90bfede9f538ebfef7356daa6a95dc4f
https://doi.org/10.1034/j.1399-0039.1999.530606.x
https://doi.org/10.1034/j.1399-0039.1999.530606.x
Autor:
Wolfgang Hagen, Sabine Walchshofer, Klaus Geissler, Wolfgang R. Sperr, Peter Valent, Erwin Tschachler, Hans-Peter Horny, Klaus Lechner, Robert Fritsche-Polanz, C Sillaber, Ilse Schwarzinger, Manuela Födinger, Ingrid Simonitsch, Andreas Chott
Publikováno v:
British Journal of Haematology. 103:740-749
A subset of patients with systemic mastocytosis (SM) develop acute myeloid leukaemia (AML). However, little is known about the biology of such leukaemias and their relationship to the mast cell (MC) lineage. We report on two female patients who suffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d94193d59cea6629399719099464e26
https://doi.org/10.1046/j.1365-2141.1998.01072.x
https://doi.org/10.1046/j.1365-2141.1998.01072.x
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Klaus Lechner, Sabine Walchshofer, N. Zojer, C Sillaber, Ingrid Simonitsch, H J Bühring, Andreas Chott, Peter Valent, Jutta Ackermann, Hans-Peter Horny, Johannes Drach, W Hagen, Josef D. Schwarzmeier
Publikováno v:
Annals of Hematology. 76:167-174
Mastocytosis is a term used for a spectrum of disorders characterized by abnormal growth and accumulation of mast cells. The cutaneous variants of the disease have to be distinguished from systemic mastocytosis (SM), in which at least one extracutane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::720c79127ade79b4e719033232eebc18
https://doi.org/10.1007/s002770050382
https://doi.org/10.1007/s002770050382
Autor:
C Sillaber, Hans Bankl, Peter Valent, Christine Marosi, Wolfgang R. Sperr, Hans-Georg Eichler, H Pirc-Danoewinata, Hermine Agis, Irene Virgolini, E. Spanblöchl
Publikováno v:
Blood. 84:4322-4332
Autonomous, factor-independent growth and differentiation of malignant cells in preleukemic and leukemic disease states is a well-recognized phenomenon and is often associated with a poor prognosis. Mast cells are distinct hematopoietic cells and exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a33143cbcb7fc8c9588264f78ab87ce
https://doi.org/10.1182/blood.v84.12.4322.bloodjournal84124322
https://doi.org/10.1182/blood.v84.12.4322.bloodjournal84124322
Autor:
C, Sillaber, H, Herrmann, K, Bennett, U, Rix, C, Baumgartner, A, Böhm, S, Herndlhofer, E, Tschachler, G, Superti-Furga, U, Jäger, P, Valent
Publikováno v:
European journal of clinical investigation. 39(12)
The multikinase inhibitor dasatinib exerts growth-inhibitory effects in patients with imatinib-resistant chronic myeloid leukaemia (CML). In first clinical trials, side effects of dasatinib, 140 mg daily, were reported to be mild and tolerable.We exa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7381eea9303006da821fc648711d17da
https://pubmed.ncbi.nlm.nih.gov/19744184
https://pubmed.ncbi.nlm.nih.gov/19744184
Autor:
K V, Gleixner, M, Mayerhofer, A, Vales, A, Gruze, G, Hörmann, S, Cerny-Reiterer, E, Lackner, E, Hadzijusufovic, H, Herrmann, A K, Iyer, M-T, Krauth, W F, Pickl, B, Marian, R, Panzer-Grümayer, C, Sillaber, H, Maeda, C, Zielinski, P, Valent
Publikováno v:
Current cancer drug targets. 9(5)
Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::359356e1b04fb9291cd720b2f00c50a8
https://pubmed.ncbi.nlm.nih.gov/19508170
https://pubmed.ncbi.nlm.nih.gov/19508170